Regulatory

October 14, 2026

Affibody Highlights Progress Across Radiopharmaceutical Pipeline at EANM 2026

Stockholm, Sweden, October 14, 2026. Affibody AB (“Affibody”) today announced a series of presentations at the 2026 Congress of the European Association of Nuclear Medicine (EANM), taking place October...

Read more

Regulatory

October 7, 2026

Affibody to Participate in the 6th Annual Needham Private Biotech & Medtech Company Virtual 1×1 Forum

Stockholm, Sweden, October 7, 2026. Affibody Medical AB (“Affibody”), a clinical stage biotechnology company developing next generation radiopharmaceuticals, today announced that management will participate in the 6th Annual Needham...

Read more

Regulatory

September 30, 2026

Affibody Announces New Izokibep Data at EADV 2026 Demonstrating Efficacy Across Patient Subgroups and Stringent Clinical Endpoints

Stockholm, Sweden, September 30, 2026. Affibody AB (“Affibody”) today announced new analyses from its global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS),...

Read more

Regulatory

August 27, 2026

Affibody to Participate in Upcoming Healthcare Investor Conferences

Stockholm, Sweden, August 27, 2026. Affibody AB (“Affibody”), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced participation in two upcoming investor conferences, delivering an...

Read more

Regulatory

May 28, 2026

First Patient Dosed in Part B of Phase 1 Study with Affibody’s Radioligand Therapy Candidate ABY-271 in HER2-positive Metastatic Breast Cancer

Stockholm, Sweden, May 28, 2026. Affibody AB (“Affibody”) today announced that the first patient has been dosed in part B of a Phase 1 clinical study with the company’s...

Read more

Regulatory

May 27, 2026

Affibody Presents First-in-Human Clinical Imaging Data with ABY-271 in HER2-positive Metastatic Breast Cancer at SNMMI 2026

Stockholm, Sweden, May 27, 2026. Affibody AB (“Affibody”) today announced that initial first-in-human clinical imaging data from the ongoing Phase 1 study with the HER2-targeting Radioligand Therapy (RLT) candidate...

Read more

Regulatory

May 21, 2026

Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at EULAR 2026

Stockholm, Sweden, May 21, 2026. Affibody AB (“Affibody”) today announced that positive 52-week data from a global Phase 2b/3 study of izokibep in psoriatic arthritis (PsA) will be presented...

Read more

Regulatory

March 27, 2026

Izokibep Demonstrates Durable Efficacy in Phase 3 Study in Hidradenitis Suppurativa as Presented at AAD 2026

Stockholm, Sweden, March 27, 2026. Affibody AB (“Affibody”) today announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa...

Read more

Regulatory

February 19, 2026

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC (“SHINE”) as an additional supplier of...

Read more